Table 3.

Change in serum hormones and growth factors from baseline to postintervention

Variable or biomarkerBaselinePostinterventionChangeP
Collected at time of RPFNA (day 1–10 of menstrual cycle)
 SHBG (with E2), nmol/L826810.46
18–22125–154−140–43
[38–124][41–92][−54–18]
90 ± 5673 ± 37−18 ± 51
 Estradiol, pg/mL88190800.001
<20a–615<20a–312−481–247
[56–131][120–224][35–129]
112 ± 115174 ± 7662 ± 136
 Estradiol, nmol/L0.320.700.290.001
<0.07a–2.28<0.07a–1.15−1.79–0.92
[0.21–0.49][0.45–0.83][0.14–0.48]
0.41 ± 0.430.64 ± 0.280.23 ± 0.51
 Bioavailable (free) estradiol, pmol/L4.58.03.50.002
0.7a–31.11.2a–15.7−25.5–10.1
[1.4–6.4][5.3–10.8][1.0–7.0]
5.3 ± 6.27.8 ± 3.42.6 ± 7.0
Collected at day 20–24 of menstrual cycle
 IGF1, ng/mL12914630.74
72–22371–220−41–66
[107–167][103–173][−15–18]
139 ± 42141 ± 412 ± 27
 IGF1, nmol/L16.819.00.40.74
9.4–29.09.3–28.6−5.4–8.6
[13.9–21.7][13.4–22.6][−1.9–2.3]
18.1 ± 5.418.3 ± 5.30.3 ± 3.5
 IGFBP3, ng/mL2,3502,6671110.051
1,505–3,6831,497–3,556−307–1,239
[2,061–3,025][2,249–3,006][−62–246]
2,504 ± 6092,618 ± 539114 ± 267
 IGFBP3, nmol/L82.393.43.90.051
52.7–128.952–124−10.7–32.6
[72.1–105.9][78.7–105.2][−2.2–8.6]
87.6 ± 21.392 ± 194.0 ± 9.3
 IGF1:IGFBP3 molar ratio0.210.19−0.010.41
0.10–0.370.10–0.42−0.12–0.11
[0.16–0.25][0.16–0.24][−0.03–0.02]
0.21 ± 0.060.21 ± 0.07−0.01 ± 0.05
 Progesterone, ng/mL3.52.80.00.78
0.4–26.20.5–36.3−10.7–30.1
[0.9–3.5][0.7–9.7][−2.6–1.9]
4.4 ± 5.57.1 ± 10.02.7 ± 9.7
 Progesterone, nmol/L11.08.9−0.10.78
1.1–83.31.5–115.3−34.1–95.8
[2.7–18.8][2.1–30.7][−8.3–6.1]
14.0 ± 17.322.6 ± 31.78.6 ± 30.7
 SHBG, nmol/L878560.53
22–27634–179−227–60
[59–193][48–135][−45–18]
117 ± 8093 ± 46−24 ± 73
 Testosterone, ng/mL0.400.580.160.002
<0.08b–2.590.19–3.52−0.21–2.33
[0.18–0.83][0.29–0.83][0.02–0.24]
0.63 ± 0.640.85 ± 0.910.22 ± 0.48
 Testosterone, nmol/L1.372.00.530.002
<0.28b–9.000.64–12.21−0.74–8.09
[0.63–2.87][1.00–2.86][0.06–0.80]
2.18 ± 2.212.93 ± 3.150.75 ± 1.66
 Bioavailable (free) testosterone, pmol/L13.417.34.10.13
1.1–120.23.8–194.4−26.9–118.2
[4.6–35.1][9.5–38.3][−2.1–8.5]
25.1 ± 30.732.4 ± 41.67.3 ± 26.8

NOTE: Median, range, [IQR], and mean ± SD are shown for the 25 subjects.

  • aOne woman had estradiol levels below limit of detection at both times and was imputed to have no change.

  • bAnother woman had testosterone levels below limit of detection only at baseline and was considered to have exhibited an increase.